VANCOUVER, British Columbia–()–Brains Bioceutical Corp. (“Brains” or the “Company”) is happy to announce the completion of a USD $31.9 million capital increase with DSM Venturing and current Brains shareholders. DSM Venturing, who acted as lead investor on this spherical, is the company enterprise arm of Royal DSM (“DSM”), a world, objective led science-based firm energetic in well being, vitamin and sustainable residing. This landmark funding and strategic transaction solidifies Brains’ place as one of many main pharmaceutical firms within the cannabinoid (CBD) sector. Del Morgan & Co. acted as Brains’ monetary agent in respect to the capital increase.

“The completion of the capital raise marks an exciting milestone for the Brains’ team. To have the confidence of DSM in this next round solidifies Brains strategic position within the pharmaceutical industry,” mentioned Brains’ CEO & Chairman Rick Brar. “The growing demand for isolated CBD Active Pharmaceutical Ingredients (API’s) within the pharmaceutical and nutraceutical industry continues to expand. Our team has worked tirelessly to position Brains as the market leader within the CBD industry. Our suite of licences has allowed Brains to scale rapidly within the industry,” Brar continued.

Pieter Wolters, Managing Director DSM Venturing, commented: “The CBD market is fast-growing, powered by increasingly strong scientific evidence that demonstrate the potential of CBD API’s in a number of therapeutic areas. Also, consumers increasingly turn to CBD’s to address health issues. Brains unparalleled expertise and manufacturing capabilities in the CBD space combined with DSM’s unique scientific and marketing capabilities in the pharmaceutical sector make this the ideal partnership to help pharmaceutical players realizing the potential of CBD’s for early stage drug development.”

Brains is considered one of a few firms on the planet producing CBD as an API for pharmaceutical functions, analysis, growth, and scientific trials. It can be one of many uncommon few producers in industrial manufacturing in Europe with EU-GMDP certification, producing CBD API for each human and veterinary use inside a MHRA licensed facility. Brains’ CBD API—its major providing to the market—comprises 99.7% CBD and nil Tetrahydrocannabinol (THC).

Advancements made by Brains within the growth of pure, pure CBD profit the scientific and well being care neighborhood on a world stage. Brains phyto-cannabinoid pure CBD API has efficiently been examined by the INRS Laboratory, a World Anti-Doping Agency (WADA) facility. These screening studies have confirmed that Brains’ CBD API is freed from THC, pesticides and different banned substances listed by WADA. Brains is first of its variety within the business to get such a affirmation from a WADA-accredited laboratory for the purity of its CBD and the absence of prohibitory substances. WADA has eliminated CBD from its banned substance checklist. All actions undertaken within the UK are in accordance with UK legislation and topic to routine, periodic inspection by UK authorities.

Brains has additionally launched its branded nutraceutical CBD “Brains Pure” merchandise in prime tier well being and wellness retail and pharmacy chains within the UK. All Brains’ merchandise—whether or not Brains-branded or white-labeled—together with a partnership with a main UK vitamin firm, will bear the ‘Brains Inside®’ trademark, offering a stamp of high quality assurance. Brains can be properly positioned to navigate the strict Novel Foods necessities within the UK from the Food Standards Association (FSA) and in Europe by the European Food Safety Authority (EFSA) for CBD merchandise. The Brains partnership with DSM Venturing will permit the corporate to benefit from strategic partnerships that DSM has developed since their preliminary inception in 1902.


Brains Bioceutical Corp. is a chief in EU-GMP-certified manufacturing of naturally sourced energetic pharmaceutical components (APIs) for the pharmaceutical and nutraceutical industries. Brains Bioceutical is without doubt one of the solely pure plant-based cannabinoid energetic pharmaceutical ingredient (API) producers in industrial manufacturing at the moment and is concerned in tutorial and scientific trials throughout the globe. Brains’ Senior Management Team is comprised of a uncommon hybrid of pharmaceutical and client items executives-having held C-suite and different senior positions with firms comparable to GW Pharma, Merck, Danone, Earthbound Farms, International Herbs, Cascadia Specialties and The Royal Navy. Brains’ wholly owned subsidiary within the UK, BSPG Laboratories, is considered one of solely a few firms that has the industrial functionality and EU-GMDP certification to supply CBD API.

About DSM Venturing

DSM Venturing is the company enterprise arm of Royal DSM – a world, purpose-led, science-based firm energetic in Nutrition, Health and Sustainable Living. DSM’s objective is to create brighter lives for all. DSM addresses with its merchandise and options a number of the world’s greatest challenges whereas concurrently creating financial, environmental and societal worth for all its stakeholders – clients, staff, shareholders, and society at giant. DSM delivers revolutionary options for human vitamin, animal vitamin, private care and aroma, medical units, inexperienced merchandise and functions, and new mobility and connectivity. DSM and its related firms ship annual web gross sales of about €10 billion with roughly 23,000 staff. The firm was based in 1902 and is listed on Euronext Amsterdam.

More info might be discovered at


This information launch comprises ahead trying statements or forward-looking info (“forward-looking statements”) throughout the that means of securities legal guidelines. Often, however not at all times, ahead trying statements might be recognized by means of phrases comparable to “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such phrases and phrases or state that sure actions, occasions or outcomes “may”, “could”, “would”, “might” or “will” be taken, happen or be achieved. All statements, aside from statements of historic truth, on this information launch are forward-looking statements and are primarily based on expectations, estimates and projections as on the date of this information launch. Any assertion that entails discussions with respect to predictions, expectations, beliefs, plans, projections, goals, assumptions, future occasions or efficiency usually are not statements of historic truth and could also be forward-looking statements. Risks, uncertainties and different components concerned with forward-looking statements may trigger precise occasions, outcomes, efficiency, prospects and alternatives to vary materially from these expressed or implied by such forward-looking statements. Although the Company believes that the assumptions and components utilized in getting ready the forward-looking statements on this information launch are affordable, there might be no assurance that such statements will show to be correct, as precise outcomes and future occasions may differ materially from these anticipated in such statements. Readers shouldn’t place undue reliance on the forward-looking statements and data contained on this information launch. The forward-looking statements included on this information launch are made as of the date of this information launch and the Company doesn’t undertake an obligation to publicly replace such forward-looking statements to replicate new info, subsequent occasions or in any other case until required by relevant securities legal guidelines.

Source link